Targeting the Mevalonate or Wnt Pathways to Overcome CAR T-Cell Resistance in TP53-Mutant AML Cells

The authors showed that CAR T-cells engaging TP53-deficient leukemia cells exhibited a prolonged interaction time, upregulated exhaustion markers, and were inefficient to control acute myeloid leukemia (AML) cell outgrowth in vitro and in vivo compared to TP53 wild-type cells.